Continuously monitor blood pressure (BP) every 2-5 minutes during the titration phase, adjusting the infusion rate based on BP response. Target BP reduction should be gradual, aiming for a decrease of approximately 20-25% of the initial elevated BP over 20-30 minutes. Simultaneously, monitor heart rate (HR) for bradycardia (less than 50 beats per minute). If significant bradycardia develops, temporarily reduce or halt the infusion rate and consider administering atropine as needed. Closely observe the patient for any signs of hypotension, such as dizziness, lightheadedness, or syncope, and immediately reduce or stop the infusion in these instances.
Respiratory Monitoring
Assess respiratory rate and rhythm. Labetalol can cause bronchospasm in susceptible individuals; be alert for wheezing, dyspnea, or increased respiratory effort. If respiratory compromise occurs, discontinue the infusion, administer bronchodilators (e. g., albuterol), and consider alternative antihypertensive therapy.
Other Important Observations
Regularly assess level of consciousness and skin perfusion. Monitor urine output to detect any signs of renal impairment. Check for any adverse effects, such as nausea, vomiting, or fatigue. Document all observations, including BP, HR, respiratory rate, infusion rate, and any adverse events, meticulously throughout the infusion process. Remember to review the patient’s medication history for potential drug interactions.
